Sobetirome
Chemical compound
From Wikipedia, the free encyclopedia
Sobetirome (GC-1) is a thyromimetic drug that binds to the thyroid hormone receptor TRβ1 preferentially compared to TRα1. It has been investigated for the treatment of dyslipidemia, obesity,[1] Pitt–Hopkins syndrome,[2] cholestatic liver disease,[3] multiple sclerosis,[4] bleomycin-induced lung fibrosis,[5] and COVID-19 caused ARDS.[6] It was designated as an orphan drug by the FDA for the treatment of X-linked adrenoleukodystrophy.[7]
| |
| Clinical data | |
|---|---|
| Other names | GC-1 |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H24O4 |
| Molar mass | 328.408 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
